WellSky and uMed Expand Home-Based Clinical Trial Access Nationwide

WellSky has partnered with uMed to broaden access to clinical research by enabling patients to join national studies from their homes. The companies report that pairing WellSky’s software, analytics, and services ecosystem with uMed’s automated clinical research registry platform will allow patients to participate remotely through WellSky’s network of more than 10,000 home-based care organizations. uMed’s ACCESS Cohorts platform is designed to help research teams build datasets that combine clinical and patient-generated information, and the collaboration aims to streamline the creation of high-quality real-world evidence.

According to the companies, the integration provides a mechanism to collect robust clinical information from individuals who wish to participate but may face logistical barriers to joining traditional trial sites. Providers are expected to benefit from improved reporting and performance measurement through access to more complete patient-reported and clinically sourced data.

Bill Miller, chairman and CEO of WellSky, stated, “Access to participate in clinical research has historically been limited for many patients, particularly those not connected to major academic medical centers. By integrating WellSky’s expansive provider network with uMed’s turnkey registry infrastructure, we are establishing a new framework for inclusive, patient-centered research that meets individuals where they are.”

The partnership aligns with WellSky’s broader strategy to expand its technology footprint across care settings. In October, the company announced a partnership with Suki, whose AI-enabled voice technology will support WellSky’s ambient listening capabilities for clinical documentation within its specialty EHR used in behavioral health, long-term acute care, and rehabilitation facilities.

Activity across the clinical trial enablement sector continues to increase as companies apply AI to monitoring, recruitment, and workflow automation. Medable offers Agent Studio, an agentic AI tool designed for clinical trial monitoring, while Alleviate Health, an Andreessen Horowitz-backed recruitment company launched in October with $4.3 million in seed funding, provides human-in-the-loop AI agents that screen participants, communicate via SMS and voice, verify eligibility, and coordinate scheduling.

Click here for the original news story.